Autoimmune Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Autoimmune Treatment Market Analysis
The autoimmune treatment market is expected to grow with a CAGR of 4.2%, over the forecast period (2022-2027).
The COVID-19 pandemic had an adverse effect on market growth. Patients with autoimmune rheumatic diseases are more likely to develop infections and cardiovascular co-morbidities, according to a research report released in June 2020 under the title "Challenges of autoimmune rheumatic disease therapy during the COVID-19 pandemic: A review" stated that they appear to have a slightly greater risk of acquiring severe forms rather than a clearly increased risk of COVID-19. In autoimmune rheumatic disorders, hydroxychloroquine does not show clinical COVID-19 prophylactic effectiveness. Therefore, the pandemic has had a adverse effect on how autoimmune illnesses are treated. Similarly, in January 2022, a different research study titled "Autoimmune complications of COVID-19" stated that in addition to the complications that patients experience during the COVID-19 disease period, there is growing evidence regarding the late-onset complications of COVID-19, of which autoimmune manifestations have drawn significant attention since the early months of the pandemic. The indications of COVID-19's ability to cause autoimmunity to include immunological thrombocytopenic purpura, autoimmune thyroid disorders, Kawasaki illness, Guillain-Barre syndrome, and the identification of autoantibodies. Patients with such diseases were therefore at higher risk. Thus, the pandemic had an adverse effect on market growth.
Increasing autoimmune disorders are expected to increase market growth. More than 2.8 million people worldwide, including about 1 million in the United States, are currently living with multiple sclerosis, according to the Atlas of Multiple Sclerosis Report from 2020. Autoimmune illnesses are becoming more prevalent, which is a problem for European nations. The Multiple Sclerosis Trust estimates that there are 2.5 million people worldwide who have multiple sclerosis, with Europe having the highest prevalence in 2020. Women experience multiple sclerosis more frequently than males. Women experience multiple sclerosis more frequently than males. Rheumatoid arthritis affects two million people, while psoriasis, one of the most prevalent autoimmune disorders, is thought to impact between 2% and 3% of the general population. One major factor driving rising usage rates is the increased understanding of autoimmune disorders as a result of programs for research, education, support, and activism. The American Autoimmune Related Disease Association (AARDA), which is committed to the eradication of autoimmune illnesses, the reduction of pain, and the socioeconomic impact of autoimmunity, designates the month of March each year as Autoimmune Disease Awareness Month (ADAM). The American Kidney Fund (AKF) launched a new patient-focused education and awareness campaign on lupus nephritis, a kidney condition caused by lupus, in February 2021. The AKF campaign gave lupus patients the much-needed information they need regarding the symptoms, diagnosis, and treatment of lupus nephritis. The advertising for AKF was created using grant funding from GlaxoSmithKline plc. Similarly, in September 2021, Scipher Medicine entered a partnership with Ventegra Inc. The collaboration will allow Ventegra to provide its customers with access to Scipher's PrismRA liquid molecular signature test, which aids in determining the most targeted medicine for rheumatoid arthritis patients (RA). Thus, the abovementioned factors are expected to increase market growth.
However, the higher cost of therapeutics, and low medical insurance coverage for autoimmune diseases are expected to hinder the market growth.
Autoimmune Treatment Market Trends
This section covers the major market trends shaping the Autoimmune Treatment Market according to our research experts:
Multiple Sclerosis segment is Expected to Hold Large Market Share
Multiple Sclerosis (MS) involves an immune-mediated process in which an abnormal response of the body's immune system is directed against the central nervous system (CNS). According to the Atlas of Multiple Sclerosis 3rd Edition, 2020, by the Multiple Sclerosis (MS) International Federation, nearly 2.8 million people worldwide are estimated to be living with multiple sclerosis, which equates to 1 in 3,000 people in the world living with MS and in countries with the highest prevalence, as many as 1 in every 300 people have MS. Also, Multiple Sclerosis prevalence has increased in every world region, rising from 2.3 million people affected in 2013 to 2.8 million in 2020. The high prevalence of MS cases globally is expected to propel the market for the studied segment. Public Health England Report titled 'Multiple sclerosis: prevalence, incidence and smoking status - data briefing' published in February 2020 reported that the estimated prevalence of multiple sclerosis was 190 cases per 100,000 population which equates to 105,800 individuals in England. In September 2020, Genentech, a member of the Roche Group, initiated an innovative Phase III clinical trial program for its investigational medicine, fenebrutinib, in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial program for Ocrevus (ocrelizumab) and a distinct Ocrevus trial specifically to support African-American and Hispanic- and Latinx-American patients with Multiple sclerosis. In March 2021, experts in the United Kingdom have planned to test a range of drugs already approved for other illnesses for the treatment of multiple sclerosis (MS) in a world-first 'mega-trial', which is a multi-armed trial named Octopus. Similarly, in March 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson received the United States Food and Drug Administration (FDA) approval for its Ponvory(ponesimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting, and active secondary-progressive forms of MS. Thus, given the increasing pipeline of drugs and new product launches along with the high prevalence of MS, the studied segment is expected to witness significant growth over the forecast period.
North America Dominates the Market and Expected to do same in the Forecast Period
North America is expected to dominate the overall autoimmune treatment market, throughout the forecast period. This is due to factors such as the rising incidence and prevalence of autoimmune diseases in the region. The United States has the highest incidence of autoimmune disorders (AD), with 15 to 30 million patients affected, according to the Autoimmune Registry, 2020. The National Institutes of Health (NIH) launched two funding opportunities in March 2021 through the initiative Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases (AMP AIM) to support research into autoimmune diseases. Additionally, in November 2020, Myriad Genetics, Inc. and Integrated Prescription Management (IPM) agreed to create an innovative program for persons with rheumatoid arthritis (RA). The government is anticipated to spend more money in the future on autoimmune illness research and development due to the demand for greater funding. A considerable improvement in the diagnosis, treatment and management of autoimmune diseases can be achieved by increased NIH funding.
Autoimmune Treatment Industry Overview
The autoimmune treatment market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are AbbVie, Amgen, Johnson & Johnson, Eli Lilly & Co., Pfizer, F. Hoffmann-La Roche AG, AstraZeneca Plc, and Bristol-Myers Squibb Co among others.
Autoimmune Treatment Market Leaders
-
AbbVie
-
Amgen
-
Johnson and Johnson
-
Eli Lilly and Company
-
Pfizer Inc.
*Disclaimer: Major Players sorted in no particular order
Autoimmune Treatment Market News
- In June 2022, Roivant Sciences and Pfizer unveiled Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality.
- In February 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) granted Revolo Biotherapeutics authorization to begin two Phase II trials of its autoimmune disease medication candidate "1805"
Autoimmune Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rise in the Prevalence of Autoimmune Diseases
- 4.2.2 Increasing Investments in Research and development
- 4.2.3 Advancements in Diagnostic Methods
-
4.3 Market Restraints
- 4.3.1 Higher Cost of Therapeutics
- 4.3.2 Low Medical Insurance Coverage for Autoimmune Diseases
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Indication
- 5.1.1 Rheumatic Disease
- 5.1.2 Diabetes
- 5.1.3 Multiple Sclerosis
- 5.1.4 Inflammatory Bowel Disease
- 5.1.5 Other Indications
-
5.2 By Drug Class
- 5.2.1 Anti-Inflammatory
- 5.2.2 Anti-Hyperglycemics
- 5.2.3 NSAIDs
- 5.2.4 Interferons
- 5.2.5 Other Drugs
-
5.3 By Sales Channel
- 5.3.1 Hospital Pharmacy
- 5.3.2 Online
- 5.3.3 Others
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbvie
- 6.1.2 Amgen Inc.
- 6.1.3 Johnson & Johnson
- 6.1.4 Eli Lilly and Company
- 6.1.5 Pfizer Inc.
- 6.1.6 F. Hoffmann-La Roche AG
- 6.1.7 Astrazeneca Plc
- 6.1.8 Bristol-Myers Squibb Co.
- 6.1.9 Lupin Limited
- 6.1.10 GlaxoSmithKline Plc
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAutoimmune Treatment Industry Segmentation
As per the scope of the report, in case of autoimmune diseases the body's immune system attacks healthy cells. The autoimmune diseases cannot be cured but they can control the intense immune response and bring down inflammation or at least reduce pain and inflammation. The Autoimmune Treatment Market is Segmented by Indication (Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Other Indications), Drug class (Anti-Inflammatory, Anti-Hyperglycemics, NSAIDs, Interferons, and Other Drugs), Sales channel (Hospital Pharmacy, Online, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Indication | Rheumatic Disease | |
| Diabetes | ||
| Multiple Sclerosis | ||
| Inflammatory Bowel Disease | ||
| Other Indications | ||
| By Drug Class | Anti-Inflammatory | |
| Anti-Hyperglycemics | ||
| NSAIDs | ||
| Interferons | ||
| Other Drugs | ||
| By Sales Channel | Hospital Pharmacy | |
| Online | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Autoimmune Treatment Market Research FAQs
What is the current Global Autoimmune Treatment Market size?
The Global Autoimmune Treatment Market is projected to register a CAGR of 4.20% during the forecast period (2024-2029)
Who are the key players in Global Autoimmune Treatment Market?
AbbVie, Amgen, Johnson and Johnson, Eli Lilly and Company and Pfizer Inc. are the major companies operating in the Global Autoimmune Treatment Market.
Which is the fastest growing region in Global Autoimmune Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Autoimmune Treatment Market?
In 2024, the North America accounts for the largest market share in Global Autoimmune Treatment Market.
What years does this Global Autoimmune Treatment Market cover?
The report covers the Global Autoimmune Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Autoimmune Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Autoimmune Treatment Industry Report
Statistics for the 2024 Global Autoimmune Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Autoimmune Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
